India, Sept. 17 -- Pharmaceutical companies can face short-term pressure when production disruptions, regulatory issues or supply-related challenges affect key products. Such issues can impact sales, margins and profitability until normal supplies resume.

For Dr. Reddy's Laboratories, the semaglutide-related disruption affected its Q1FY27 performance. With the company expecting commercial supplies to resume in November, the coming quarters could be important for its earnings recovery.

With a market capitalisation of Rs. 97,824 cr, the shares of Dr Reddys Laboratories Ltdclosed at Rs. 1,172.05 per share, up from its previous close of Rs. 1,145.25 per share.

Dr Reddy's Q1FY27 Performance Dr. Reddy's Laboratories reported a weak Q1FY27 ...